Answers are grounded in this paper and cite their sources.
The goal of this clinical report aimed to emphasise the significance of early detection of adverse medication responses for individuals who have taken dapagliflozin during the management of type 2 diabetes.These reactions include loose stools and diarrhoea.On June 1, 2022, a 58-year-old female patient that body weighs 49 kg and has had type 2 diabetes for the past 8 years, presented to the outpatient department of a tertiary care hospital with complaints of uncontrolled diabetes (since 3 years) and lower leg pain.The specialist examined and assessed the patient.On June 2, 2022, the patient experienced 8-10 episodes of diarrhoea and loose stools, following the administration of the drug.The likelihood of experiencing loose stools or diarrhoea when taking dapagliflozin increases with age, drugdrug interactions, genetic polymorphism, and gender.This is one of the first reports pointing to loose stools and diarrhoea as possible adverse medication reactions associated with dapagliflozin.The need for monitoring dapagliflozin medication in clinics and hospitals is highlighted by this case.The requirement for patient self-monitoring as well as the usage of a risk assessment tool to determine a patient's risk.
No takes yet. Share an insight, caveat, or question.
Ajmal et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: